诚信认证：
工商注册信息已核实！
快速导航
产品分类
微信二维码
Minisite
QQ号咨询
细胞凋亡
ABT-199 (GDC-0199)
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
产品参数
| 货号 | CAS号 | 操作 |
|---|---|---|
| A124869-100mg | 1257044-40-8 | 询价 |
| A124869-10mg | 1257044-40-8 | 询价 |
| A124869-25mg | 1257044-40-8 | 询价 |
| A124869-50mg | 1257044-40-8 | 询价 |
| A124869-5mg | 1257044-40-8 | 询价 |
产品介绍
属性
| 折光率 | 1.64 |
| 溶解性 | Soluble in DMSO (100 mg/ml (~115mM) at 25 °C), water (<1 mg/ml (< 1mM) at 25 °C), and ethanol (<1 mg/ml (< 1mM) at 25 °C). |
| 存贮条件 | 储存温度-20°C |
描述
| 应用 | A Bcl-2-selective inhibitor with Ki of <0.01 nM |
| 产品介绍 | ABT-199 (GDC-0199)是高效的Bcl-2选择性抑制剂，Ki为0.01 nM，比对Bcl-xL和Bcl-w的抑制性高4800倍以上，对Mcl-1无活性。 |
| 备注 | ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 2. |
| 生化机理 | ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, currently in clinical trials. ABT-199 inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers. |
| 别名 | GDC-0199;GDC-0199;ABT199;ABT 199;GDC0199;GDC 0199;Venetoclax ; abt 199;4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-benzamide |
ABT-199 (GDC-0199)信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于ABT-199 (GDC-0199)报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途